BHVN
Biohaven Ltd.
NYSE · Healthcare · Biotechnology · US
$15.69
−1.07%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 2.1M | 4.1M | — | — | — |
| Gross Profit | (2.1M) | (4.1M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 467.8M | 635.1M | 795.9M | 373.3M | 437.1M |
| SG&A Expense | 99.7M | 106.2M | 89.2M | 62.8M | 130.9M |
| General & Admin Expense | 99.7M | 106.2M | 89.2M | 62.8M | 130.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.1M) | — | — | — | — |
| Total Operating Expenses | 565.4M | 741.2M | 885.1M | 436.1M | 567.9M |
| Cost and Expenses | 567.4M | 745.4M | 885.1M | 436.1M | 567.9M |
| Operating Income (EBIT) | (567.4M) | (745.4M) | (885.1M) | (436.1M) | (567.9M) |
| Non-Operating | |||||
| Interest Income | 6.2M | 14.6M | 21.3M | 17.7M | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 6.2M | 14.6M | 21.3M | 17.7M | — |
| Other Non-Op Income/Expense | (18.2M) | 8.0M | 39.4M | 26.5M | (1.9M) |
| Non-Operating Income (excl Interest) | 18.2M | (8.0M) | (39.4M) | (26.5M) | 1.9M |
| EBT (Pre-Tax Income) | (585.6M) | (737.4M) | (845.7M) | (409.6M) | (569.8M) |
| Income Tax Expense | 1.2M | 1.4M | 735.0K | (1.4M) | 438.0K |
| Bottom Line | |||||
| Net Income | (586.8M) | (738.8M) | (846.4M) | (408.2M) | (570.3M) |
| Earnings from Cont. Ops | (586.8M) | (738.8M) | (846.4M) | (408.2M) | (570.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (586.8M) | (738.8M) | (846.4M) | (408.2M) | (570.3M) |
| Per Share | |||||
| Basic EPS | ($4.64) | ($6.86) | ($9.28) | ($5.73) | ($12.75) |
| Diluted EPS | ($4.64) | ($6.86) | ($9.28) | ($5.73) | ($12.75) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 150.6M | 107.6M | 91.2M | 71.2M | 44.7M |
| Diluted Shares Outstanding | 150.6M | 107.6M | 91.2M | 71.2M | 44.7M |
| Profitability Metrics | |||||
| EBITDA | (574.9M) | (727.5M) | (837.8M) | (402.6M) | (568.5M) |
| D&A | 10.7M | 9.9M | 7.9M | 6.9M | 1.4M |
| EBIT | (585.6M) | (737.4M) | (845.7M) | (409.6M) | (569.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026